Daratumumab and isatuximab treatment of MM cell lines results in upregulation of CD46 and CD59 and escape during a second mAb treatment round. Escape can be reduced by pretreatment with Ad35K++ and/or rIlyd4. Here, CD59 is linked to Miyoshi myopathy.